18 July, 2017
According to Zacks, "Array BioPharma Inc.is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases".
Stock market analysts watching Array BioPharma Inc. Jane Street Grp Limited Liability stated it has 0% of its portfolio in Array Biopharma Inc (NASDAQ:ARRY). The stock's current distance from 20-Day Simple Moving Average (SMA20) is 0.37% where SMA50 and SMA200 are 4.66% and -1.84% respectively. During the same period in the prior year, the firm earned ($0.16) earnings per share. 895,498 shares of the company's stock were exchanged. Its down 0.58, from 1.88 in 2016Q3. 36 funds opened positions while 55 raised stakes. 158.02 million shares or 7.81% more from 146.57 million shares in 2016Q3 were reported. The hedge fund held 4.99 million shares of the major pharmaceuticals company at the end of 2016Q4, valued at $43.83M, down from 6.46 million at the end of the previous reported quarter. The company reported the earnings of $-0.21/Share in the last quarter where the estimated EPS by analysts was $-0.16/share. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/07/16/array-biopharma-inc-arry-receives-average-rating-of-hold-from-brokerages.html. Shares for $1.99M were sold by ANDREWS CHARLES ELLIOTT.
Shaker Financial Services Llc holds 0.73% of its portfolio in Cohen & Steers Clsd-End Optuny Fnd, Inc. for 105,406 shares. Brandywine Global Inv Management Lc owns 309,338 shares for 0.04% of their portfolio. Meeder Asset Mngmt holds 464 shares. The company presently has a consensus rating of "Hold" and a consensus price target of $11.54.
Analysts expect Array Biopharma Inc (NASDAQ:ARRY) to report $-0.21 EPS on August, 3.They anticipate $0.04 EPS change or 23.53% from last quarter's $-0.17 EPS. The Return on Equity (ROE) value stands at 0%.
08/05/2016 - Array BioPharma Inc. had its " rating reiterated by analysts at Stifel Nicolaus. California Pub Employees Retirement Systems owns 245,500 shares or 0% of their United States portfolio.
Toyota Motor Corporation has a consensus hold rating from 2 Wall Street analysts, and the number of shares now sold short amount to at least 0.07% of shares outstanding. The Germany-based Deutsche Bank & Trust Ag has invested 0.02% in Array Biopharma Inc (NASDAQ:ARRY). Therefore 75% are positive. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. According to these analysts, the Low Revenue Estimate for Array BioPharma Inc.is 13 Million and the High Revenue Estimate is 37 Million. The stock has "Buy" rating by Jefferies on Monday, June 12. Next Grp Inc accumulated 0% or 1,250 shares. The rating was initiated by Suntrust Robinson with "Buy" on Friday, June 3. J P Morgan Chase & Co raised Array BioPharma from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $9.00 to $10.00 in a report on Wednesday, May 3rd. Cowen and Company cut their target price on shares of Array BioPharma to $14.00 and set an outperform rating for the company in a research note on Monday, March 20th. The firm has "Sector Weight" rating by KeyBanc Capital Markets given on Friday, December 18. Jefferies maintained Array Biopharma Inc (NASDAQ:ARRY) on Monday, June 12 with "Buy" rating. Stifel Nicolaus maintained Array Biopharma Inc (NASDAQ:ARRY) rating on Friday, February 3. Cantor Fitzgerald maintained the shares of ARRY in report on Tuesday, May 30 with "Buy" rating.
Since March 28, 2017, it had 0 buys, and 2 selling transactions for $633,150 activity.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
